Get the Stockscreener App
11.57
6.93%
0.75
After Hours:
11.60
0.03
+0.26%
Forte Biosciences Inc stock is traded at $11.57, with a volume of 14,993.
It is up +6.93% in the last 24 hours and up +22.43% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$10.82
Open:
$10.99
24h Volume:
14,993
Relative Volume:
0.16
Market Cap:
$76.17M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-11.12
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
+13.71%
1M Performance:
+22.43%
6M Performance:
-3.58%
1Y Performance:
+49.29%
1-Day Range:
$10.99
$11.79
1-Week Range:
$9.91
$11.79
52-Week Range:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
11.57 | 132.15M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Is Forte Biosciences Inc.’s ROIC above industry average2025 Market Outlook & Advanced Technical Signal Analysis - thegnnews.com
Is this a good reentry point in Forte Biosciences Inc.Market Sentiment Summary & Stepwise Entry/Exit Trade Alerts - Newser
Real time social sentiment graph for Forte Biosciences Inc.Market Rally & Scalable Portfolio Growth Methods - Newser
Long term hold vs stop loss in Forte Biosciences Inc.July 2025 Technicals & Fast Moving Trade Plans - Newser
Published on: 2025-08-16 05:15:06 - Newser
Automated trading signals detected on Forte Biosciences Inc.Market Trend Report & Fast Exit Strategy with Risk Control - Newser
Forte Biosciences (NASDAQ:FBRX) Raised to “Hold” at Wall Street Zen - Defense World
Short interest data insights for Forte Biosciences Inc.July 2025 Rallies & Short-Term High Return Strategies - Newser
Identifying reversal signals in Forte Biosciences Inc.Gap Down & Verified Momentum Stock Watchlist - Newser
FBRX: Chardan Capital Maintains Buy Rating, $61 Target Unchanged - AInvest
Using data filters to optimize entry into Forte Biosciences Inc.July 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
Live market analysis of Forte Biosciences Inc.July 2025 Trends & Growth Oriented Trade Recommendations - Newser
Real time alert setup for Forte Biosciences Inc. performanceJuly 2025 Outlook & Fast Exit/Entry Strategy Plans - Newser
how forte biosciences inc. stock performs during market volatilityNew Guidance & Verified Swing Trading Watchlist - Newser
Relative strength of Forte Biosciences Inc. in sector analysisProfit Target & AI Powered Market Entry Strategies - Newser
This Forte Biosciences Insider Increased Their Holding By 273% Last Year - Yahoo Finance
What recovery options are there for Forte Biosciences Inc.2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
Forte Biosciences Announces Q2 2025 Results and Trials - MSN
What MACD and RSI say about Forte Biosciences Inc.Analyst Downgrade & Consistent Profit Trade Alerts - Newser
How to build a custom watchlist for Forte Biosciences Inc.Quarterly Market Review & Fast Gain Stock Trading Tips - Newser
Forte Biosciences Announces Q2 Results and Business Update: Initiates 3 Clinical Trials for FB102 - AInvest
Forte Biosciences, Inc. Announces Results and Provides Update - The Joplin Globe
Forte Advances Treatment Pipeline for Celiac Disease, Vitiligo, and Alopecia with $106M War Chest - Stock Titan
Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
What indicators show strength in Forte Biosciences Inc.Weekly Stock Summary & AI Powered Market Entry Ideas - Newser
How to forecast Forte Biosciences Inc. trends using time seriesWeekly Trend Summary & Safe Capital Growth Plans - Newser
Using Python tools to backtest Forte Biosciences Inc. strategiesJuly 2025 Closing Moves & Target Return Focused Stock Picks - Newser
Applying chart zones and confluence areas to Forte Biosciences Inc.Portfolio Return Summary & Daily Entry Point Trade Alerts - Newser
Using Ichimoku Cloud for Forte Biosciences Inc. technicalsRate Hike & Daily Growth Stock Investment Tips - Newser
Multi factor analysis applied to Forte Biosciences Inc.Intraday Price Action Forecast Planner - Newser
Analyzing Forte Biosciences Inc. with multi timeframe chartsShort Term Gain Strategy with AI Logic - Newser
Forte Biosciences (FBRX) to Release Earnings on Wednesday - Defense World
What’s the recovery path for long term holders of Forte Biosciences Inc.Strategy Playbook for Risk Controlled Trades - Newser
Forte Biosciences FBRX 2025Q2 Earnings Preview Upside Potential on Strong Revenue Projections - AInvest
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):